Earlier today it was announced that the FDA has approved a new production facility for the manufacture of flu vaccines. The facility, based in the U.S. is owned by sanofi pasteur, (a division of our client sanofi-aventis) which manufactures Fluzone Influenza Virus Vaccine. This new facility will greatly increase sanofi pasteur’s production capability.
Congratulations to them. (Send some Fluzone our way!)
The FDA is playing catch up, again. On the heels of requiring the dreaded black box warning for Botox and similar products, the FDA today announced it would also require black box warnings for two testosterone replacement products: AndroGel 1% and Testim 1%.
After having been on the market for some time, the FDA has decided that the products could have negative effects if children are exposed to the products.
Mary Roberts, an FDA medical officer, said in some instances people were applying the product to their chest and then holding their children without wearing shirts.
You may view the FDA’s press release here.